Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Integrating pharmacokinetics and pharmacodynamics in operational research to End TB.

Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, McIlleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB.

Clin Infect Dis. 2019 Sep 27. pii: ciz942. doi: 10.1093/cid/ciz942. [Epub ahead of print]

PMID:
31560376
2.

Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in The Netherlands.

Gafar F, Van't Boveneind-Vrubleuskaya N, Akkerman OW, Wilffert B, Alffenaar JC.

Eur Respir J. 2019 Sep 12. pii: 1901402. doi: 10.1183/13993003.01402-2019. [Epub ahead of print]

PMID:
31515410
3.

Respiratory syncytial virus infection morbidity in the elderly; time for repurposing of ribavirin?

de Zwart AES, Riezebos-Brilman A, Kerstjens HAM, Verschuuren EAM, Alffenaar JC.

Clin Infect Dis. 2019 Aug 24. pii: ciz835. doi: 10.1093/cid/ciz835. [Epub ahead of print] No abstract available.

PMID:
31504299
4.

Treatment of MDR-TB using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules.

Bolhuis MS, van der Werf TS, Kerstjens HAM, de Lange WCM, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Aug 22. pii: 1900580. doi: 10.1183/13993003.00580-2019. [Epub ahead of print] No abstract available.

PMID:
31439686
5.

Performance of a web-based application measuring spot quality in dried blood spot sampling.

Veenhof H, Koster RA, Brinkman R, Senturk E, Bakker SJL, Berger SP, Akkerman OW, Touw DJ, Alffenaar JC.

Clin Chem Lab Med. 2019 Aug 2. pii: /j/cclm.ahead-of-print/cclm-2019-0437/cclm-2019-0437.xml. doi: 10.1515/cclm-2019-0437. [Epub ahead of print]

PMID:
31373896
6.

Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015.

Pradipta IS, Van't Boveneind-Vrubleuskaya N, Akkerman OW, Alffenaar JC, Hak E.

Antimicrob Resist Infect Control. 2019 Jul 12;8:115. doi: 10.1186/s13756-019-0561-z. eCollection 2019.

7.

In vitro evaluation of an intravenous microdialysis catheter for therapeutic drug monitoring of gentamicin and vancomycin.

van der Mast JE, Nijsten MW, Alffenaar JC, Touw DJ, Bult W.

Pharmacol Res Perspect. 2019 Jun 26;7(4):e00483. doi: 10.1002/prp2.483. eCollection 2019 Aug.

8.

Repurposed oral ribavirin for respiratory virus infections requires pharmacokinetic-pharmacodynamics for dose optimization.

de Zwart AES, Riezebos-Brilman A, Kerstjens HAM, Verschuuren EAM, Alffenaar JC.

Clin Infect Dis. 2019 Jul 4. pii: ciz593. doi: 10.1093/cid/ciz593. [Epub ahead of print] No abstract available.

PMID:
31271195
9.

Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring.

Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, Keevil BG, Koch BCP, Linden R, Pistos C, Stolk LM, Touw DJ, Stove CP, Alffenaar JC.

Ther Drug Monit. 2019 Aug;41(4):409-430. doi: 10.1097/FTD.0000000000000643.

PMID:
31268966
10.

Quality Assessment of Dried Blood Spots from Tuberculosis Patients from Four Countries.

Zuur MA, Veenhof H, Aleksa A, Boveneind-Vrubleuskaya NV', Darmawan E, Hasnain MG, Heysell SK, Jongedijk EM, Koster RA, Magis-Escurra C, Martinez N, Molinas G, Mondal D, Mulyani UA, Perwitasari DA, Tsivunchyk A, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Jun 4. doi: 10.1097/FTD.0000000000000659. [Epub ahead of print]

PMID:
31169760
11.

Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.

Märtson AG, Veringa A, van den Heuvel ER, Bakker M, Touw DJ, van der Werf TS, Span LFR, Alffenaar JC.

Mycoses. 2019 Aug;62(8):698-705. doi: 10.1111/myc.12948. Epub 2019 Jun 18. Review.

PMID:
31145490
12.

Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.

Wang Y, Bahar MA, Jansen AME, Kocks JWH, Alffenaar JC, Hak E, Wilffert B, Borgsteede SD.

J Antimicrob Chemother. 2019 Oct 1;74(10):2848-2864. doi: 10.1093/jac/dkz221.

PMID:
31127283
13.

Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs.

Alffenaar JC, Sintchenko V, Marais BJ.

Clin Infect Dis. 2019 Apr 26. pii: ciz334. doi: 10.1093/cid/ciz334. [Epub ahead of print] No abstract available.

PMID:
31125392
14.

Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.

Dekkers BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, van der Werf TS, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Sep 5;54(3). pii: 1900373. doi: 10.1183/13993003.00373-2019. Print 2019 Sep. No abstract available.

PMID:
31048350
15.

Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, Manika K, Kioumis IP, van der Werf TS, Johnson JL, Peloquin C, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00384-19. doi: 10.1128/AAC.00384-19. Print 2019 Jul.

PMID:
31010868
16.

Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.

Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutse RE, Magis-Escurra C, Kosterink JGW, van der Werf TS, Alffenaar JC, Sturkenboom MGG.

Clin Pharmacokinet. 2019 Apr 17. doi: 10.1007/s40262-019-00763-3. [Epub ahead of print]

PMID:
30997650
17.

Relevance of the drug-drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat.

Dekkers BGJ, Bierman WFW, Touw DJ, Alffenaar JC.

AIDS. 2019 May 1;33(6):1100-1102. doi: 10.1097/QAD.0000000000002162. No abstract available.

18.

Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients.

Veenhof H, Koster RA, Alffenaar JC, van den Berg AP, de Groot MR, Verschuuren EAM, Berger SP, Bakker SJL, Touw DJ.

Clin Chem Lab Med. 2019 Apr 2. pii: /j/cclm.ahead-of-print/cclm-2019-0053/cclm-2019-0053.xml. doi: 10.1515/cclm-2019-0053. [Epub ahead of print]

PMID:
30939110
19.

Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review.

Lutfiana NC, van Boven JFM, Masoom Zubair MA, Pena MJ, Alffenaar JC.

Br J Clin Pharmacol. 2019 Jul;85(7):1407-1417. doi: 10.1111/bcp.13935. Epub 2019 May 17. Review.

20.

A volumetric absorptive microsampling LC-MS/MS method for five immunosuppressants and their hematocrit effects.

Koster RA, Niemeijer P, Veenhof H, Hateren KV, Alffenaar JC, Touw DJ.

Bioanalysis. 2019 Mar;11(6):495-508. doi: 10.4155/bio-2018-0312. Epub 2019 Mar 20.

PMID:
30892068
21.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):253-254. doi: 10.1097/FTD.0000000000000597. No abstract available.

PMID:
30883521
22.

Ganciclovir Therapeutic Drug Monitoring: A Case Series.

Märtson AG, Touw D, Damman K, Bakker M, Oude Lansink-Hartgring A, van der Werf T, Knoester M, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):107-110. doi: 10.1097/FTD.0000000000000598. Erratum in: Ther Drug Monit. 2019 Jun;41(3):408.

23.

Tuberculosis-Related Malnutrition: Public Health Implications.

Ter Beek L, Alffenaar JC, Bolhuis MS, van der Werf TS, Akkerman OW.

J Infect Dis. 2019 Jun 19;220(2):340-341. doi: 10.1093/infdis/jiz091. No abstract available.

PMID:
30835281
24.

Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02379-18. doi: 10.1128/AAC.02379-18. Print 2019 May.

PMID:
30782999
25.

Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Eur Respir J. 2019 Apr 18;53(4). pii: 1802107. doi: 10.1183/13993003.02107-2018. Print 2019 Apr. No abstract available.

PMID:
30655280
26.

Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.

Perwitasari DA, Darmawan E, Mulyani UA, Vlies PV, Alffenaar JC, Atthobar J, Wilffert B.

Int J Mycobacteriol. 2018 Oct-Dec;7(4):380-386. doi: 10.4103/ijmy.ijmy_143_18.

27.

Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625.

PMID:
30496467
28.

Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.

Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S303-S307. doi: 10.1093/cid/ciy613.

PMID:
30496466
29.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

PMID:
30496460
30.

Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.

Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S267-S273. doi: 10.1093/cid/ciy608.

PMID:
30496455
31.

Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.

Daskapan A, Tran QTD, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y, Bierman WFW, Kosterink JGW, van der Werf TS, Proost JH, Alffenaar JC, Touw DJ.

Ther Drug Monit. 2019 Feb;41(1):59-65. doi: 10.1097/FTD.0000000000000576.

32.

Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned.

Alffenaar JC, Tiberi S, Migliori GB.

Lancet Infect Dis. 2019 Jan;19(1):3-4. doi: 10.1016/S1473-3099(18)30549-8. Epub 2018 Nov 23. No abstract available.

PMID:
30477962
33.

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb.

34.

Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens.

Milliken E, de Zwart AES, Alffenaar JC, Marriott DJE, Riezebos-Brilman A, Schteinman A, Evans AM, Glanville AR, Verschuuren EAM, Reuter SE.

J Antimicrob Chemother. 2019 Mar 1;74(3):691-698. doi: 10.1093/jac/dky466.

PMID:
30452661
35.

A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, Touw DJ, Andersen AB, Bekker A, Denti P, Hemanth Kumar AK, Jeremiah K, Kwara A, McIlleron H, Meintjes G, van Oosterhout JJ, Ramachandran G, Rockwood N, Wilkinson RJ, van der Werf TS, Alffenaar JC.

Clin Pharmacokinet. 2019 Jun;58(6):747-766. doi: 10.1007/s40262-018-0716-8. Review.

36.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

37.

Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy.

Gafar F, Arifin H, Jurnalis YD, Yani FF, Fitria N, Alffenaar JC, Wilffert B.

Pediatr Infect Dis J. 2019 Jan;38(1):50-53. doi: 10.1097/INF.0000000000002192.

PMID:
30234790
38.

Therapeutic Drug Monitoring: The Need for Practical Guidance.

Alffenaar JC, Heysell SK, Mpagama SG.

Clin Infect Dis. 2019 Mar 5;68(6):1065-1066. doi: 10.1093/cid/ciy787. No abstract available.

PMID:
30219826
39.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

40.

Invasive Candidiasis in the Elderly: Considerations for Drug Therapy.

Dekkers BGJ, Veringa A, Marriott DJE, Boonstra JM, van der Elst KCM, Doukas FF, McLachlan AJ, Alffenaar JC.

Drugs Aging. 2018 Sep;35(9):781-789. doi: 10.1007/s40266-018-0576-9. Review.

41.

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Pieterman ED, Te Brake LHM, de Knegt GJ, van der Meijden A, Alffenaar JC, Bax HI, Aarnoutse RE, de Steenwinkel JEM.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01354-18. doi: 10.1128/AAC.01354-18. Print 2018 Sep.

42.

Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin.

Boonstra JM, Jongedijk EM, Koster RA, Touw DJ, Alffenaar JC.

Bioanalysis. 2018 Jun 1;10(11):877-886. doi: 10.4155/bio-2017-0275. Epub 2018 Jun 4.

PMID:
29863416
43.

Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.

PMID:
29697766
44.

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.

Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, Caws M, Tiberi S, Bolhuis M, Alffenaar JC, Davies G, Sloan DJ.

J Antimicrob Chemother. 2018 Jul 1;73(7):1755-1762. doi: 10.1093/jac/dky096.

45.

Pound foolish and penny wise-when will dosing of rifampicin be optimised?

Magis-Escurra C, Anthony RM, van der Zanden AGM, van Soolingen D, Alffenaar JC.

Lancet Respir Med. 2018 Apr;6(4):e11-e12. doi: 10.1016/S2213-2600(18)30044-4. Epub 2018 Jan 29. No abstract available.

PMID:
29396032
46.

Lack of penetration of amikacin into saliva of tuberculosis patients.

van den Elsen SHJ, Akkerman OW, Huisman JR, Touw DJ, van der Werf TS, Bolhuis MS, Alffenaar JC.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702024. doi: 10.1183/13993003.02024-2017. Print 2018 Jan. No abstract available.

47.

New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State.

Caño-Muñiz S, Anthony R, Niemann S, Alffenaar JC.

Clin Microbiol Rev. 2017 Nov 29;31(1). pii: e00060-17. doi: 10.1128/CMR.00060-17. Print 2018 Jan. Review.

48.

Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention.

Nguyen TVA, Anthony RM, Bañuls AL, Nguyen TVA, Vu DH, Alffenaar JC.

Clin Infect Dis. 2018 May 2;66(10):1625-1630. doi: 10.1093/cid/cix992.

PMID:
29126225
49.

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.

van den Elsen SHJ, Oostenbrink LM, Heysell SK, Hira D, Touw DJ, Akkerman OW, Bolhuis MS, Alffenaar JC.

Ther Drug Monit. 2018 Feb;40(1):17-37. doi: 10.1097/FTD.0000000000000462. Review.

50.

Risk factors contributing to a low darunavir plasma concentration.

Daskapan A, Stienstra Y, Kosterink JGW, Bierman WFW, van der Werf TS, Touw DJ, Alffenaar JC.

Br J Clin Pharmacol. 2018 Mar;84(3):456-461. doi: 10.1111/bcp.13464. Epub 2017 Dec 7.

Supplemental Content

Loading ...
Support Center